enGene (NASDAQ:ENGN) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

enGene (NASDAQ:ENGN) posted its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06, Zacks reports.

enGene Trading Up 0.5 %

NASDAQ:ENGN opened at $5.96 on Friday. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $8.16 and its 200 day moving average is $7.81. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The stock has a market capitalization of $263.53 million, a PE ratio of -3.66 and a beta of -0.78.

Insider Buying and Selling

In related news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the purchase, the chief executive officer now owns 10,000 shares in the company, valued at $57,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Growth Opportunities F. Forbion purchased 5,997 shares of the firm’s stock in a transaction dated Friday, October 4th. The shares were bought at an average price of $6.54 per share, for a total transaction of $39,220.38. Following the completion of the transaction, the insider now owns 2,457,989 shares of the company’s stock, valued at approximately $16,075,248.06. This trade represents a 0.24 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ENGN shares. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Morgan Stanley restated an “overweight” rating and set a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price objective on shares of enGene in a report on Friday, December 6th. Citizens Jmp raised enGene to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Raymond James began coverage on enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $30.38.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.